Evidence map›Paper›PMID 42553268›Full record

ArticleAnnals of neurosciences2026

Sertraline and Escitalopram But Not Other Antidepressants Increase Acetylcholinesterase Activity

Jahnavi Dharwadkar, Amrutha R Nayak, B S Shankaranarayana Rao, Bettadapura N Srikumar

Abstract read
In one paragraph

Article in Annals of neurosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jahnavi DharwadkarDepartment of Pharmacy, Birla Institute of Technology and Science, Pilani, Hyderabad Campus, Hyderabad, Telangana, India.ORCID https://orcid.org/0009-0002-0492-7260
Amrutha R NayakDepartment of Neurophysiology, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bengaluru, Karnataka, India.ORCID https://orcid.org/0009-0008-9102-3764
B S Shankaranarayana RaoDepartment of Neurophysiology, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bengaluru, Karnataka, India.ORCID https://orcid.org/0000-0002-8323-8211
Bettadapura N SrikumarDepartment of Neurophysiology, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bengaluru, Karnataka, India.ORCID https://orcid.org/0000-0001-9162-0990

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Abstract. Background: Depression is a pervasive mental health disorder that has been extensively studied, but effective treatment remains elusive. This is due to the lack of understanding regarding the underlying molecular mechanisms. Antidepressants usually target the monoaminergic system, but studies show that other neurotransmitters, such as acetylcholine (ACh), may be involved. Many clinical and preclinical studies show that increased ACh levels are associated with depression. Particularly, acetylcholinesterase (AChE) activity is shown to decrease in depression and antidepressants are known to increase it. However, it is not known whether this effect is direct or downstream. Purpose: To check whether antidepressants can directly modulate AChE activity, we evaluated the effect of various classes of antidepressants on Methods: Briefly, sertraline (SER), escitalopram (ESC), amitriptyline (AT), duloxetine (DUL), bupropion (BUP) and ketamine (KET) were incubated with the brain tissue homogenates in a 96-well plate for 30 min, following which AChE activity was evaluated by modified Ellman's method. Results: SER and ESC increased AChE activity in the frontal cortex, while AT, DUL, BUP and KET did not affect it. Conclusion: This points to a novel mechanism of action of selective serotonin reuptake inhibitors (SSRIs) and a potential target for developing new therapeutics with better efficacy and lower side effect profiles.

Indexed as

acetylcholineduloxetineEscitalopramfrontal cortexhippocampusketamine

Identifiers

PMID42553268
PMCPMC13433566

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.